Optimizing Outcomes in Newly Diagnosed Multiple Myeloma: The Role of CD38 Monoclonal Antibodies – A Clinical Commentary Activity
Released On
January 17, 2025
Expires On
January 17, 2026
Media Type
Internet
Completion Time
45 minutes
Specialty
Hematology-Oncology
Topics
Multiple Myeloma, Oncology
Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi.
Credit Available
- Physicians - maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity was designed for medical oncologists, hematologists, advanced practice professionals, and nurses who treat and manage patients with multiple myeloma.
Program Overview
New data on quadruplet regimens offer more therapeutic options to patients with multiple myeloma. Topics discussed include the role of minimal residual disease, recent clinical trial results (eg, CEPHEUS, PERSEUS, IMROZ, and IsKia), and patient quality of life.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Appraise the clinical implications of recent anti-CD38 antibody studies for patients with multiple myeloma
- Outline key factors that may affect longitudinal application of anti-CD38 antibody agents in patients with multiple myeloma
Faculty
Saad Z. Usmani, MD, MBA, FACP
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center (MSK)
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT
Memorial Sloan Cancer Center
New York, New York
Ajay Chari, MD
Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
Luciano Costa, MD, PhD
Professor, Hematology & Oncology
School of Medicine
The University of Alabama at Birmingham
Birmingham, Alabama
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Ajay Chari, MD
Consultant: AbbVie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Millenium/Takeda, Sanofi/Genzyme
Researcher: Janssen
Luciano Costa, MD, PhD
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson
Honorarium: Adaptive Biotechnologies
Research Grants: AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson
Saad Z. Usmani, MD, MBA, FACP
Consultant: AbbVie, Amgen, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura
Research: Amgen, Array Biopharma, Bristol Myers Squibb, EdoPharm
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of January 17, 2025 through January 17, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].